AOD-9604

AOD-9604 was developed in the late 1990s (specifically 1998) by researchers at Monash University in Australia. The goal was to isolate the fat-burning (lipolytic) properties of Human Growth Hormone without inducing insulin resistance or cellular growth. What it is: AOD-9604 is a synthetic peptide containing a 16-amino-acid C-terminal fragment of human growth hormone (residues 177-191 with an added tyrosine). It is categorized as an adipolytic peptide designed to promote fat loss. Proposed Mechanisms & Research Findings: It acts by stimulating beta-3 adrenergic receptors and lipolysis in adipose tissue while inhibiting lipogenesis. Unlike intact growth hormone, it does not bind to the growth hormone receptor, meaning it does not increase IGF-1 levels or promote cellular proliferation. Regulatory & Safety Status: It is not FDA approved. Clinical development was halted after Phase IIb obesity trials failed to show consistent efficacy across a large population. Sourcing from unregulated online vendors carries high purity risks. Athletic & Anti-Doping Status: AOD-9604 is strictly prohibited by WADA under Section S2 (Peptide Hormones and Growth Factors) as a growth-hormone related substance. Any use in- or out-of-competition constitutes a doping violation.